Emblem to Begin Trading on the TSX Venture

emblem-social-logo
Emblem Corp. Goes Public under Symbol EMC.V

TORONTO, ONTARIO–(Marketwired – Dec. 8, 2016) – After much anticipation from the North American investment community, Emblem Corp. (TSXV: EMC) is set to go public tomorrow morning and begin trading on the TSX-V under the symbol EMC.V. Emblem Cannabis Corporation, a wholly-owned subsidiary of Emblem Corp. is a Canadian licensed producer of medical cannabis.

Emblem becomes the latest of the major licensed producers in Canada to go public, something that has been generating a tremendous amount of activity in financial circles in Canada, the United States, and Europe.
Based in Paris, Ontario, Emblem is going public at a time when legalization is firmly on the political horizon, and the number of medical marijuana patients keeps climbing as the medical community begins to embrace the benefits of cannabis to treat a range of medical conditions.

Tomorrow’s listing on the TSX-V represents the culmination of years of incredibly hard work by a very dedicated team who believe very strongly in the medical benefits of cannabis. Our listing on the exchange is just the beginning of a new chapter for our company, and for the future of cannabis in this country.

Gordon Fox KindCannGord Fox, CEO of Emblem Cannabis Corporation

In less than a year, the number of medical marijuana patients in Canada has more than doubled with over 90,000 Canadians now registered and patient registrations continues to grow at 10% per month on average. This trend clearly demonstrates that not only is the stigma of cannabis beginning to disappear, but attitudes within the medical community are now shifting.

Emblem’s unique pharmaceutical-like cannabinoid formulation approach is focused on optimizing strain selection and greatly expanding acceptance of medical marijuana therapy by both patients and healthcare professionals. It’s always been known that Cannabinoids have real therapeutic value, as evidenced by Cesamet, Marinol and Sativex all having been approved as prescription drugs. The active components in cannabis are extracted, purified, and incorporated into advanced dosage formulations.

Some of the conditions that have been identified by the scientific and medical community that respond well to cannabis therapy include chronic pain, post-traumatic stress disorder, seizures, nausea, fibromyalgia and more.

As for the recreational market, the Liberal government’s task force on legalization is on track and has made it clear that the government would like to see all aspects of the business highly regulated, including cultivation – something that will position Emblem Cannabis well for a market that according to Deloitte could be worth as much as $22.6 billion annually.

About Emblem Cannabis Corp.

Emblem Corp. is a fully integrated Canadian medical marijuana, healthcare and cannabinoid-based pharmaceutical company licensed to carry on business as a producer of medical cannabis by the Government of Canada.

Original press release: http://www.marketwired.com/press-release/emblem-corp-goes-public-under-symbol-emcv-2181942.htm


Update 12/09:

Emblem Corp. announced today that final regulatory approval of the trading date for its shares on the TSX-V, originally announced as December 9, 2016, has been deferred. The likely trading date will be Monday December 12, 2016. Emblem will issue an additional press release confirming its trading date during business hours on December 9.

Trading will take place on the TSX-V under the symbol EMC.V.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter